Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 54.82% is 155% above its 5-year average of 21.54%, near the low end of its 5-year range (0.00%–943.75%).
4.20% above its 12-month average of 52.61%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 45.94%.
NET PROFIT MARGIN
54.82%
NET PROFIT MARGIN AVG TTM
52.61%
NET PROFIT MARGIN AVG 3Y
35.89%
NET PROFIT MARGIN AVG 5Y
21.54%
NET PROFIT MARGIN AVG 10Y
10.92%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.20%
CURRENT VS 3Y AVG
+52.72%
CURRENT VS 5Y AVG
+154.54%
CURRENT VS 10Y AVG
+401.81%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+21184.62%
vs the sector median at left
Krystal Biotech, Inc.
Market Cap
$9.63B
Net Profit Margin
54.82%
TTM Avg
52.61%
3Y Avg
35.89%
5Y Avg
21.54%
Market Cap
$9.63B
Net Profit Margin
2.96%
TTM Avg
3.05%
3Y Avg
3.43%
5Y Avg
3.79%
Market Cap
$9.85B
Net Profit Margin
5.29%
TTM Avg
1.30%
3Y Avg
7.86%
5Y Avg
11.15%
Market Cap
$9.92B
Net Profit Margin
8.59%
TTM Avg
-21.22%
3Y Avg
-48.94%
5Y Avg
16.61%
Market Cap
$10.00B
Net Profit Margin
6.90%
TTM Avg
6.89%
3Y Avg
6.71%
5Y Avg
6.89%
Market Cap
$9.24B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
Market Cap
$10.12B
Net Profit Margin
9.99%
TTM Avg
10.36%
3Y Avg
10.48%
5Y Avg
22.21%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $9.63B | 54.82% | 52.61% | 35.89% | 21.54% |
| Henry Schein, Inc. (HSIC)vs › | $9.63B | 2.96% | 3.05% | 3.43% | 3.79% |
| Vaxcyte, Inc. (PCVX)vs › | $9.49B | 0.00% | 0.00% | 0.00% | 0.00% |
| Repligen Corporation (RGEN)vs › | $9.85B | 5.29% | 1.30% | 7.86% | 11.15% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.92B | 8.59% | -21.22% | -48.94% | 16.61% |
| Insulet Corp. (PODD)vs › | $9.31B | 12.29% | 14.66% | 10.46% | 7.35% |
| The Ensign Group, Inc. (ENSG)vs › | $10.00B | 6.90% | 6.89% | 6.71% | 6.89% |
| Bruker Corporation (BRKR)vs › | $9.24B | -2.03% | 1.55% | 7.31% | 8.11% |
| Align Technology, Inc. (ALGN)vs › | $10.12B | 9.99% | 10.36% | 10.48% | 22.21% |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | -598.56% | -1557.47% | -67611.49% | -57374.18% |
Operating Margin
44.9%
Net Profit Margin
54.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 45.94% |
| 2026-03-31 | 48.07% |
| 2025-12-31 | 47.99% |
| 2025-09-30 | 81.15% |
| 2025-06-30 | 39.91% |
| 2025-03-31 | 40.52% |
| 2024-12-31 | 49.90% |
| 2024-09-30 | 32.42% |
| 2024-06-30 | 22.15% |
| 2024-03-31 | 2.06% |
| 2023-12-31 | 20.63% |
| 2023-09-30 | 943.75% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -986.72% |
| 2019-03-31 | -705.15% |
| 2018-12-31 | -361.05% |
| 2018-09-30 | -1269.59% |
| 2018-06-30 | -1315.61% |
| 2018-03-31 | -1692.91% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
